Ahn-Gook Pharmaceutical Co. Ltd Net Assets
Ahn-Gook Pharmaceutical Co. Ltd net assets. Based on the latest financial reports, Ahn-Gook Pharmaceutical Co. Ltd (001540) has net assets worth ₩167.29 Billion KRW (≈ $113.37 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩303.42 Billion ≈ $205.63 Million USD) and total liabilities (₩136.13 Billion ≈ $92.25 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset momentum of Ahn-Gook Pharmaceutical Co. Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩167.29 Billion |
| % of Total Assets | 55.13% |
| Annual Growth Rate | 3.05% |
| 5-Year Change | 14.97% |
| 10-Year Change | 26.41% |
| Growth Volatility | 4.48 |
Net Assets of Ahn-Gook Pharmaceutical Co. Ltd (2011–2024)
Net assets of Ahn-Gook Pharmaceutical Co. Ltd from 2011 to 2024. This chart illustrates how Ahn-Gook Pharmaceutical Co. Ltd's net assets have evolved over time, based on quarterly financial data. See Ahn-Gook Pharmaceutical Co. Ltd balance sheet quality to measure how much of total assets are equity-financed.
Annual Net Assets for Ahn-Gook Pharmaceutical Co. Ltd (2011–2024)
The table below shows the annual net assets of Ahn-Gook Pharmaceutical Co. Ltd from 2011 to 2024. For live market cap and overall valuation, see Ahn-Gook Pharmaceutical Co. Ltd (001540) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ₩165.68 Billion ≈ $112.28 Million |
+9.24% |
| 2023-12-31 | ₩151.67 Billion ≈ $102.78 Million |
-2.02% |
| 2022-12-31 | ₩154.80 Billion ≈ $104.90 Million |
+6.57% |
| 2021-12-31 | ₩145.26 Billion ≈ $98.44 Million |
+0.81% |
| 2020-12-31 | ₩144.10 Billion ≈ $97.65 Million |
-2.80% |
| 2019-12-31 | ₩148.25 Billion ≈ $100.46 Million |
+1.01% |
| 2018-12-31 | ₩146.77 Billion ≈ $99.46 Million |
+7.16% |
| 2017-12-31 | ₩136.96 Billion ≈ $92.81 Million |
+4.63% |
| 2016-12-31 | ₩130.89 Billion ≈ $88.70 Million |
-0.13% |
| 2015-12-31 | ₩131.06 Billion ≈ $88.82 Million |
+7.02% |
| 2014-12-31 | ₩122.46 Billion ≈ $82.99 Million |
-3.13% |
| 2013-12-31 | ₩126.42 Billion ≈ $85.67 Million |
+10.54% |
| 2012-12-31 | ₩114.36 Billion ≈ $77.50 Million |
+2.03% |
| 2011-12-31 | ₩112.08 Billion ≈ $75.96 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Ahn-Gook Pharmaceutical Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14507001651000.0% over the analyzed period, indicating profitable operations and earnings retention.
Ahn-Gook Pharmaceutical Co. Ltd Net Assets Breakdown (December 2024)
Ahn-Gook Pharmaceutical Co. Ltd net assets breakdown by equity component as of December 2024.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩145.07 Billion | 87.56% |
| Common Stock | ₩6.52 Billion | 3.94% |
| Other Components | ₩14.08 Billion | 8.50% |
| Total Equity | ₩165.68 Billion | 100.00% |
Ahn-Gook Pharmaceutical Co. Ltd Competitors by Market Cap
The table below lists competitors of Ahn-Gook Pharmaceutical Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
I&C Technology Co. Ltd
KQ:052860
|
$73.41 Million |
|
Mnc Investama Tbk
JK:BHIT
|
$73.43 Million |
|
5E Advanced Materials Inc
AU:5EA
|
$73.44 Million |
|
Huadian Ener-B
SHG:900937
|
$73.44 Million |
|
Hanjin Heavy Ind & Const Holdings Co Ltd
KO:003480
|
$73.37 Million |
|
Huikwang
TWO:6508
|
$73.34 Million |
|
Can One Bhd
KLSE:5105
|
$73.33 Million |
|
Igis Residence Reit Co Ltd
KO:350520
|
$73.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Ahn-Gook Pharmaceutical Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 152,086,315,460 to 165,675,787,270, a change of 13,589,471,810 (8.9%).
- Net income of 16,845,463,600 contributed positively to equity growth.
- Dividend payments of 2,500,380,300 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩16.85 Billion | +10.17% |
| Dividends Paid | ₩2.50 Billion | -1.51% |
| Other Changes | ₩-755.61 Million | -0.46% |
| Total Change | ₩- | 8.94% |
Book Value vs Market Value Analysis
This analysis compares Ahn-Gook Pharmaceutical Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.65x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.83x to 0.65x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩11423.53 | ₩9530.00 | x |
| 2017-12-31 | ₩11951.85 | ₩9530.00 | x |
| 2018-12-31 | ₩12807.77 | ₩9530.00 | x |
| 2019-12-31 | ₩12936.96 | ₩9530.00 | x |
| 2020-12-31 | ₩12574.97 | ₩9530.00 | x |
| 2021-12-31 | ₩12726.23 | ₩9530.00 | x |
| 2022-12-31 | ₩13620.12 | ₩9530.00 | x |
| 2023-12-31 | ₩13381.56 | ₩9530.00 | x |
| 2024-12-31 | ₩14577.25 | ₩9530.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Ahn-Gook Pharmaceutical Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 10.17%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 6.21%
- • Asset Turnover: 0.90x
- • Equity Multiplier: 1.83x
- Recent ROE (10.17%) is above the historical average (3.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 5.80% | 4.98% | 0.79x | 1.47x | ₩-4.68 Billion |
| 2012 | 3.19% | 2.57% | 0.84x | 1.48x | ₩-7.74 Billion |
| 2013 | 5.18% | 4.23% | 0.94x | 1.30x | ₩-6.06 Billion |
| 2014 | -1.12% | -0.81% | 0.94x | 1.47x | ₩-13.54 Billion |
| 2015 | 7.14% | 4.74% | 1.00x | 1.51x | ₩-3.74 Billion |
| 2016 | 1.31% | 0.99% | 0.89x | 1.50x | ₩-11.37 Billion |
| 2017 | 5.96% | 4.44% | 0.88x | 1.52x | ₩-5.54 Billion |
| 2018 | 9.01% | 7.12% | 0.87x | 1.45x | ₩-1.46 Billion |
| 2019 | 1.71% | 1.63% | 0.72x | 1.47x | ₩-12.29 Billion |
| 2020 | -0.91% | -0.92% | 0.71x | 1.40x | ₩-15.73 Billion |
| 2021 | 2.71% | 2.41% | 0.77x | 1.46x | ₩-10.59 Billion |
| 2022 | 4.44% | 3.35% | 0.92x | 1.45x | ₩-8.60 Billion |
| 2023 | 0.85% | 0.55% | 0.98x | 1.57x | ₩-13.92 Billion |
| 2024 | 10.17% | 6.21% | 0.90x | 1.83x | ₩277.88 Million |
Industry Comparison
This section compares Ahn-Gook Pharmaceutical Co. Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $490,498,627,337
- Average return on equity (ROE) among peers: 5.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Ahn-Gook Pharmaceutical Co. Ltd (001540) | ₩167.29 Billion | 5.80% | 0.81x | $73.40 Million |
| Dongwha Pharm.Co.Ltd (000020) | $229.62 Billion | 7.70% | 0.48x | $98.05 Million |
| Yuhan Corp. (000100) | $1.12 Trillion | 8.27% | 0.18x | $3.84 Billion |
| Yuhan Corp Preferred (000105) | $2.36 Trillion | 8.22% | 0.36x | $45.29 Million |
| Yuyu Pharma (000220) | $82.83 Billion | 5.48% | 0.47x | $40.03 Million |
| Yuyu Pharma Inc (000225) | $78.29 Billion | 7.52% | 0.42x | $13.08 Million |
| Yuyu Pharma Inc (000227) | $78.29 Billion | 7.52% | 0.42x | $32.56 Million |
| Ildong Holdings Co Ltd (000230) | $349.98 Billion | 5.99% | 1.02x | $43.17 Million |
| Samil Pharm (000520) | $70.03 Billion | 11.32% | 0.65x | $108.19 Million |
| Donga Socio Holdings (000640) | $306.84 Billion | 8.70% | 1.30x | $379.59 Million |
| Jw Pharmac (001060) | $230.09 Billion | -10.98% | 1.49x | $349.95 Million |
About Ahn-Gook Pharmaceutical Co. Ltd
Ahn-Gook Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products. The company's pharmaceutical products include Cinatura and Revo Tension. The company was founded in 1959 and is headquartered in Seoul, South Korea.